The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer

J. Yu; Q. Cao; J. Yu; L. Wu; A. Dallol; J. Li; G. Chen; C. Grasso; X. Cao; R. J. Lonigro; S. Varambally; R. Mehra; N. Palanisamy; J. Y. Wu; F. Latif; A. M. Chinnaiyan

doi:10.1038/onc.2010.269

The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer

J. Yu, Q. Cao, J. Yu, L. Wu, A. Dallol, J. Li, G. Chen, C. Grasso, X. Cao, R. J. Lonigro, S. Varambally, R. Mehra, N. Palanisamy, J. Y. Wu, F. Latif, A. M. Chinnaiyan

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer.

Original language	English (US)
Pages (from-to)	5370-5380
Number of pages	11
Journal	Oncogene
Volume	29
Issue number	39
DOIs	https://doi.org/10.1038/onc.2010.269
State	Published - Sep 30 2010

Funding

This study was supported in part by the NIH Prostate Specialized Program of Research Excellence Grants P50CA69568 and P50CA090386, Early Detection Research Network Grant UO1 111275 (to AMC), the NIH 1R01CA132874-01A1 (to AMC), CA114197 and CA107193 (to JYW) and K99CA129565-01A1 (to JY), the US Department of Defense PC051081 (to AMC) and PC080665 (to JY), and the James S McDonnell Foundation Grant JSMF (to JYW) and Searle Foundation (to JYW). AMC is supported by a Burroughs Welcome Foundation Award in Clinical Translational Research, a Doris Duke Charitable Foundation Distinguished Clinical Investigator Award, the Prostate Cancer Foundation and the Howard Hughes Medical Institute. AMC is an American Cancer Society Research Professor.

Keywords

DNA hypermethylation
EZH2
Epigenetic silencing
Polycomb group proteins
Prostate cancer
SLIT2

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/onc.2010.269

Cite this

@article{cf95dfc430db4483aa5e1e4b6d91f33b,

title = "The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer",

abstract = "The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer.",

keywords = "DNA hypermethylation, EZH2, Epigenetic silencing, Polycomb group proteins, Prostate cancer, SLIT2",

author = "J. Yu and Q. Cao and J. Yu and L. Wu and A. Dallol and J. Li and G. Chen and C. Grasso and X. Cao and Lonigro, {R. J.} and S. Varambally and R. Mehra and N. Palanisamy and Wu, {J. Y.} and F. Latif and Chinnaiyan, {A. M.}",

note = "Funding Information: This study was supported in part by the NIH Prostate Specialized Program of Research Excellence Grants P50CA69568 and P50CA090386, Early Detection Research Network Grant UO1 111275 (to AMC), the NIH 1R01CA132874-01A1 (to AMC), CA114197 and CA107193 (to JYW) and K99CA129565-01A1 (to JY), the US Department of Defense PC051081 (to AMC) and PC080665 (to JY), and the James S McDonnell Foundation Grant JSMF (to JYW) and Searle Foundation (to JYW). AMC is supported by a Burroughs Welcome Foundation Award in Clinical Translational Research, a Doris Duke Charitable Foundation Distinguished Clinical Investigator Award, the Prostate Cancer Foundation and the Howard Hughes Medical Institute. AMC is an American Cancer Society Research Professor.",

year = "2010",

month = sep,

day = "30",

doi = "10.1038/onc.2010.269",

language = "English (US)",

volume = "29",

pages = "5370--5380",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "39",

}

TY - JOUR

T1 - The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer

AU - Yu, J.

AU - Cao, Q.

AU - Yu, J.

AU - Wu, L.

AU - Dallol, A.

AU - Li, J.

AU - Chen, G.

AU - Grasso, C.

AU - Cao, X.

AU - Lonigro, R. J.

AU - Varambally, S.

AU - Mehra, R.

AU - Palanisamy, N.

AU - Wu, J. Y.

AU - Latif, F.

AU - Chinnaiyan, A. M.

N1 - Funding Information: This study was supported in part by the NIH Prostate Specialized Program of Research Excellence Grants P50CA69568 and P50CA090386, Early Detection Research Network Grant UO1 111275 (to AMC), the NIH 1R01CA132874-01A1 (to AMC), CA114197 and CA107193 (to JYW) and K99CA129565-01A1 (to JY), the US Department of Defense PC051081 (to AMC) and PC080665 (to JY), and the James S McDonnell Foundation Grant JSMF (to JYW) and Searle Foundation (to JYW). AMC is supported by a Burroughs Welcome Foundation Award in Clinical Translational Research, a Doris Duke Charitable Foundation Distinguished Clinical Investigator Award, the Prostate Cancer Foundation and the Howard Hughes Medical Institute. AMC is an American Cancer Society Research Professor.

PY - 2010/9/30

Y1 - 2010/9/30

N2 - The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer.

AB - The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer.

KW - DNA hypermethylation

KW - EZH2

KW - Epigenetic silencing

KW - Polycomb group proteins

KW - Prostate cancer

KW - SLIT2

UR - http://www.scopus.com/inward/record.url?scp=77957589668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957589668&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.269

DO - 10.1038/onc.2010.269

M3 - Article

C2 - 20622896

AN - SCOPUS:77957589668

SN - 0950-9232

VL - 29

SP - 5370

EP - 5380

JO - Oncogene

JF - Oncogene

IS - 39

ER -

The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this